ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.51 USD
-0.03 (-5.19%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $0.52 +0.01 (1.56%) 5:44 PM ET
2-Buy of 5 2
A Value B Growth F Momentum B VGM
Income Statements
Fiscal Year end for ASLAN Pharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 12 | 0 | 0 | 0 | 3 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 48 | 34 | 16 | 48 |
Income After Depreciation & Amortization | 0 | -48 | -34 | -16 | -46 |
Non-Operating Income | NA | 0 | 4 | 1 | 0 |
Interest Expense | NA | 4 | 2 | 1 | 1 |
Pretax Income | NA | -51 | -32 | -17 | -47 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | -1 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -44 | -51 | -32 | -17 | -47 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -44 | -51 | -31 | -16 | -47 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -48 | -34 | -16 | -45 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -48 | -34 | -16 | -46 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 16.45 | 13.95 | 13.03 | 7.69 | 6.50 |
Diluted EPS Before Non-Recurring Items | -2.69 | -3.68 | -2.40 | -2.00 | -3.70 |
Diluted Net EPS (GAAP) | -2.69 | -3.68 | -2.40 | -2.00 | -7.25 |
Fiscal Year end for ASLAN Pharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 12.00 | 0.00 |
Cost Of Goods | NA | NA | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | NA | 0.00 | 12.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 10.42 | 14.37 | 18.11 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -10.42 | -2.37 | -18.11 |
Non-Operating Income | NA | NA | 1.87 | 1.66 | 0.07 |
Interest Expense | NA | NA | 1.13 | 1.13 | 1.07 |
Pretax Income | NA | NA | -9.68 | -1.83 | -19.11 |
Income Taxes | NA | NA | 0.03 | 0.06 | 0.01 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.51 | -9.71 | -1.89 | -19.11 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.51 | -9.71 | -1.89 | -19.11 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 17.28 | 17.20 | 16.44 | 14.83 |
Diluted EPS Before Non-Recurring Items | NA | -0.78 | -0.56 | -0.11 | -1.29 |
Diluted Net EPS (GAAP) | NA | -0.78 | -0.56 | -0.11 | -1.29 |